FindTrial
Sign In

CB-103

DRUG4 trials

Sponsors

Cellestia Biotech AG, MedSIR, M.D. Anderson Cancer Center, Michael J. Dennis, MD

Conditions

Adenoid Cystic CarcinomaAdvanced Breast CancerBreast CancerColorectal CancerGlomus Tumor, MalignantHepatocellular CarcinomaLeukemiaLeukemia, Lymphoblastic

Phase 1

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
TerminatedNCT03422679
Cellestia Biotech AGAdenoid Cystic Carcinoma, Breast Cancer, Colorectal Cancer +5
Start: 2017-12-05End: 2022-11-11Updated: 2024-01-16
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
RecruitingNCT05774899
Michael J. Dennis, MDAdenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Start: 2023-06-01End: 2028-06-01Target: 32Updated: 2026-09-09

Phase 2

CB-103 Plus NSAI In Luminal Advanced Breast Cancer
TerminatedNCT04714619
MedSIRAdvanced Breast Cancer
Start: 2021-05-06End: 2022-04-26Updated: 2023-12-19
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
TerminatedNCT05464836
M.D. Anderson Cancer CenterLeukemia, Leukemia, Lymphoblastic
Start: 2023-04-06End: 2024-08-12Updated: 2025-11-26

Related Papers

Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.
2024-11-124 citations
Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.
Journal of Clinical Oncology2021-05-2023 citations
First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.
Journal of Clinical Oncology2018-05-2012 citations